Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
BTG International Limited has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This matter is assigned to a distinct examiner, SAEED, KAMAL A, who is the busiest examiner for the portfolio with 1 pending office action. All current prosecution activity is located within a distinct art unit. This profile shows a highly concentrated prosecution environment for the company's current biotechnology filings.
For a practitioner, the focus is entirely on the 1 pending office action and the specific requirements of SAEED, KAMAL A. With only a distinct examiner and a distinct art unit, there is no diversification of the workload. The success of the company's current active filing in the Biotechnology & Pharmaceuticals sector depends on navigating the specific feedback from the single assigned examiner. This streamlined structure suggests a very specific technical focus for the company's current patent efforts, with no other active matters to provide a broader context for examiner behavior. The 1 pending office action is the critical path for the company's immediate goals.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SAEED, KAMAL A | 1 | 83.8% | +9.8% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18893063 | PLATINUM-RESISTANT CANCER TREATMENT | SAEED, KAMAL A | — |
| Art Unit | Apps |
|---|---|
| 1626 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18893063 | PLATINUM-RESISTANT CANCER TREATMENT | SAEED, KAMAL A | 1626 | DP | Non-Final OA | — | Pending | Sep 23, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialBTG International Limited has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Kamal A Saeed has the most, with 1 of BTG International Limited's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
